AI-generated · cited to primary sources · not investment advice
Aurobindo Pharma (524804) Jun 2025 Filing Analysis
How durable is the business?
The US business grew by 13% year-on-year, driven by volume gains and a large product portfolio that helped maintain price stability despite industry-wide erosion. (3 expanding, 2 contracting)
“For the quarter, the revenue from US formulation increased by 13% year-on-year to Rs. 4,072 crores... Revenue from US formulation increased by 7% to Rs. 14,816 crores”
The API segment showed modest growth of 2% for the full year, driven by higher volumes and improved asset utilization. (2 expanding, 2 contracting)
“For the full year, API business contributed around 14% and clocked a revenue of Rs. 4,323 crores... registering a growth of 2%.”
See the full cited Business Model analysis of Aurobindo Pharma
What could break the thesis?
Risk has intensified due to a fire incident at the Pen-G facility in Kakinada, which caused a temporary halt in operations and requires new regulatory approvals (Consent to Operate) to restart. (1 intensifying, 3 easing, 1 stable)
“due to the incident, we had temporarily halted the plant operations... we have submitted the renewal application for Consent to Operate. The production will resume promptly upon receiving the necessary approvals”
See the full cited Risk analysis of Aurobindo Pharma
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.